A Phase III, Multicenter, Uncontrolled, Open-label Study to Evaluate Safety and Immunogenicity of Begrivac, Preservative Free, Inactivated Split Influenza Vaccine, Using the Strain Composition 2010/2011 When Administered to Adult and Elderly Subjects.
Phase of Trial: Phase III
Latest Information Update: 04 Jan 2012
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Novartis
- 04 Jan 2012 Actual patient number (142) added as reported by ClinicalTrials.gov.
- 23 Aug 2010 New trial record